Back to Search Start Over

Quality of Life after Deep Brain Stimulation of Pediatric Patients With Dyskinetic Cerebral Palsy: A Prospective, Single-Arm, Multicenter Study With a Subsequent Randomized Double-Blind Crossover (STIM-CP)

Authors :
Koy, Anne
Kuehn, Andrea A.
Huebl, Julius
Schneider, Gerd-Helge
van Riesen, Anne K.
Eckenweiler, Matthias
Rensing-Zimmermann, Cornelia
Coenen, Volker Arnd
Krauss, Joachim K.
Saryyeva, Assel
Hartmann, Hans
Haeussler, Martin
Volkmann, Jens
Matthies, Cordula
Horn, Annette
Schnitzler, Alfons
Vesper, Jan
Gharabaghi, Alireza
Weiss, Daniel
Bevot, Andrea
Marks, Warren
Pomykal, Angela
Monbaliu, Elegast
Borck, Guntram
Mueller, Joerg
Prinz-Langenohl, Reinhild
Dembek, Till
Visser-Vandewalle, Veerle
Wirths, Jochen
Schiller, Petra
Hellmich, Martin
Timmermann, Lars
Koy, Anne
Kuehn, Andrea A.
Huebl, Julius
Schneider, Gerd-Helge
van Riesen, Anne K.
Eckenweiler, Matthias
Rensing-Zimmermann, Cornelia
Coenen, Volker Arnd
Krauss, Joachim K.
Saryyeva, Assel
Hartmann, Hans
Haeussler, Martin
Volkmann, Jens
Matthies, Cordula
Horn, Annette
Schnitzler, Alfons
Vesper, Jan
Gharabaghi, Alireza
Weiss, Daniel
Bevot, Andrea
Marks, Warren
Pomykal, Angela
Monbaliu, Elegast
Borck, Guntram
Mueller, Joerg
Prinz-Langenohl, Reinhild
Dembek, Till
Visser-Vandewalle, Veerle
Wirths, Jochen
Schiller, Petra
Hellmich, Martin
Timmermann, Lars

Abstract

Background Patients with dyskinetic cerebral palsy are often severely impaired with limited treatment options. The effects of deep brain stimulation (DBS) are less pronounced than those in inherited dystonia but can be associated with favorable quality of life outcomes even in patients without changes in dystonia severity. Objective The aim is to assess DBS effects in pediatric patients with pharmacorefractory dyskinetic cerebral palsy with focus on quality of life. Methods The method used is a prospective, single-arm, multicenter study. The primary endpoint is improvement in quality of life (CPCHILD [Caregiver Priorities & Child Health Index of Life with Disabilities]) from baseline to 12 months under therapeutic stimulation. The main key secondary outcomes are changes in Burke-Fahn-Marsden Dystonia Rating Scale, Dyskinesia Impairment Scale, Gross Motor Function Measure-66, Canadian Occupational Performance Measure (COPM), and Short-Form (SF)-36. After 12 months, patients were randomly assigned to a blinded crossover to receive active or sham stimulation for 24 hours each. Severity of dystonia and chorea were blindly rated. Safety was assessed throughout. The trial was registered at ClinicalTrials.gov, number NCT02097693. Results Sixteen patients (age: 13.4 +/- 2.9 years) were recruited by seven clinical sites. Primary outcome at 12-month follow-up is as follows: mean CPCHILD increased by 4.2 +/- 10.4 points (95% CI [confidence interval] -1.3 to 9.7; P = 0.125); among secondary outcomes: improvement in COPM performance measure of 1.1 +/- 1.5 points (95% CI 0.2 to 1.9; P = 0.02) and in the SF-36 physical health component by 5.1 +/- 6.2 points (95% CI 0.7 to 9.6; P = 0.028). Otherwise, there are no significant changes. Conclusion Evidence to recommend DBS as routine treatment to improve quality of life in pediatric patients with dyskinetic cerebral palsy is not yet sufficient. Extended follow-up in larger cohorts will determine the impact of DBS further to guide trea

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1312207988
Document Type :
Electronic Resource